Latest & greatest articles for mesalamine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on mesalamine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on mesalamine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for mesalamine

1. Mesalamine

Mesalamine Top results for mesalamine - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for mesalamine The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines

Trip Latest and Greatest2018

2. Mesalamine (5-ASA) for the prevention of recurrent diverticulitis.

Mesalamine (5-ASA) for the prevention of recurrent diverticulitis. BACKGROUND: Diverticular disease is a common condition that increases in prevalence with age. Recent theories on the pathogenesis of diverticular inflammation have implicated chronic inflammation similar to that seen in ulcerative colitis. Mesalamine, or 5-aminosalicylic acid (5-ASA), is a mainstay of therapy for individuals with ulcerative colitis. Accordingly, 5-ASA has been studied for prevention of recurrent diverticulitis (...) . OBJECTIVES: To evaluate the efficacy of mesalamine (5-ASA) for prevention of recurrent diverticulitis. SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2017, Issue 8), in the Cochrane Library; Ovid MEDLINE (from 1950 to 9 September 2017); Ovid Embase (from 1974 to 9 September 2017); and two clinical trials registries for ongoing trials - Clinicaltrials.gov and the World Health Organization (WHO) International Clinical Trials Registry Platform database (9 September

Cochrane2017

3. Budesonide is more effective than mesalamine or placebo in short-term treatment of collagenous colitis

Budesonide is more effective than mesalamine or placebo in short-term treatment of collagenous colitis 24440672 2014 04 18 2014 06 05 2014 10 30 1528-0012 146 5 2014 May Gastroenterology Gastroenterology Budesonide is more effective than mesalamine or placebo in short-term treatment of collagenous colitis. 1222-30.e1-2 10.1053/j.gastro.2014.01.019 S0016-5085(14)00076-6 Studies reporting that budesonide is effective for the treatment of collagenous colitis have been small and differed (...) in efficacy measures. Mesalamine has been proposed as a treatment option for collagenous colitis, although its efficacy has never been investigated in placebo-controlled trials. We performed a phase 3, placebo-controlled, multicenter study to evaluate budesonide and mesalamine as short-term treatments for collagenous colitis. Patients with active collagenous colitis were randomly assigned to groups given pH-modified release oral budesonide capsules (9 mg budesonide once daily, Budenofalk, n = 30

EvidenceUpdates2014 Full Text: Link to full Text with Trip Pro

4. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study.

Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. Oral mesalamine (Asacol) for mild... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 1991 ) Volume: 115 , Issue: 5 , Pages: 350-355 PubMed: Available from or Find this paper at: Abstract OBJECTIVE: To evaluate the efficacy and safety of a pH-sensitive, polymer-coated oral preparation (...) of mesalamine in patients with mildly to moderately active ulcerative colitis. DESIGN: A multicenter, double-blind, placebo-controlled randomized trial. SETTING: Five university-based medical centers, one inflammatory bowel disease center, and three private practice sites. PATIENTS: A total of 158 patients with newly or previously diagnosed active ulcerative colitis. INTERVENTION: A pH-sensitive, polymer-coated oral preparation of mesalamine (5-aminosalicylic acid) was used at 1.6 and 2.4 g/d for 6 weeks

Annals of Internal Medicine2013

5. Once-daily versus multiple-daily mesalamine for patients with ulcerative colitis: a meta-analysis

Once-daily versus multiple-daily mesalamine for patients with ulcerative colitis: a meta-analysis Once-daily versus multiple-daily mesalamine for patients with ulcerative colitis: a meta-analysis Once-daily versus multiple-daily mesalamine for patients with ulcerative colitis: a meta-analysis Tong JL, Huang ML, Xu XT, Qiao YQ, Ran ZH CRD summary The authors concluded that the efficacy and safety of once-daily mesalamine was comparable to multiple-daily mesalamine for the maintenance treatment (...) of ulcerative colitis and was more effective for inducing remission in active ulcerative colitis. The evidence suggests that this conclusion may be reliable where it relates to quiescent ulcerative colitis, but subject to more uncertainty for active disease. Authors' objectives To compare the efficacy and safety of once-daily mesalamine versus multiple-daily mesalamine for the treatment of ulcerative colitis. Searching MEDLINE, EMBASE, Science Citation Index, and Cochrane Central Register of Controlled

DARE.2012

6. Once-Daily MMX(R) Mesalamine for Endoscopic Maintenance of Remission of Ulcerative Colitis

Once-Daily MMX(R) Mesalamine for Endoscopic Maintenance of Remission of Ulcerative Colitis 22565161 2012 07 06 2012 10 24 2013 11 21 1572-0241 107 7 2012 Jul The American journal of gastroenterology Am. J. Gastroenterol. Once-daily MMX(®) mesalamine for endoscopic maintenance of remission of ulcerative colitis. 1064-77 10.1038/ajg.2012.103 Treatment with mesalamine to maintain endoscopic remission (mucosal healing) of ulcerative colitis (UC) has been shown to reduce the risk of relapse (...) and is the recommended first-line maintenance therapy. To improve treatment adherence, a mesalamine formulation that can be administered once-daily, MMX(®) mesalamine (Lialda; Shire Pharmaceuticals LLC, Wayne, PA), was developed. This study was conducted to determine the efficacy and safety of once-daily MMX mesalamine compared with twice-daily delayed-release mesalamine (Asacol; Warner Chilcott, Dublin, Ireland) for maintaining endoscopic remission in patients with UC. A multicenter, randomized, double-blind, 6

EvidenceUpdates2012

7. Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn`s disease

Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn`s disease 21070781 2011 01 31 2011 03 28 2013 11 21 1528-0012 140 2 2011 Feb Gastroenterology Gastroenterology Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease. 425-434.e1; quiz e13-4 10.1053/j.gastro.2010.11.004 Comparative data on budesonide vs mesalamine for the treatment of mild-to-moderately active Crohn's (...) disease (CD) are sparse. We assessed the efficacy and safety of each therapy in patients with mildly to moderately active CD. We performed a randomized, double-blind, double-dummy, 8-week, multicenter study in which 309 patients with mildly to moderately active CD received pH-modified-release oral budesonide (9 mg/day once daily or 3 mg/day 3 times daily) or Eudragit-L-coated oral mesalamine (4.5 g/day). The primary efficacy variable, clinical remission (defined as Crohn's Disease Activity Index ≤150

EvidenceUpdates2011

8. Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis

Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis Ford AC, Khan KJ, Sandborn WJ, Kane SV, Moayyedi P CRD (...) summary Once-daily dosing of mesalamine was as effective as conventional dosing in preventing relapse of quiescent ulcerative colitis and there were no significant differences in compliance or adverse events. The authors' conclusions reflect the evidence presented but given the small number of variable studies with limitations in quality, they should be interpreted with caution. Authors' objectives To compare once-daily dosing versus conventional dosing of 5-aminosalicylates and relapse of quiescent

DARE.2011

9. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis

Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis 20064514 2010 03 29 2010 04 20 2013 11 21 1528-0012 138 4 2010 Apr Gastroenterology Gastroenterology Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. 1286-96, 1296.e1-3 10.1053/j.gastro.2009.12.054 The practice of dosing (...) mesalamines in divided doses for the treatment of ulcerative colitis (UC) began with sulfasalazine and was driven by sulfapyridine toxicity. This convention and the assumption that dosing multiple times a day is necessary to treat UC had not been challenged until recently. This study was conducted to determine the efficacy and safety of once-daily dosing of delayed-release mesalamine (Asacol 400-mg tablets) compared with twice-daily dosing for maintaining remission in UC patients. A multicenter

EvidenceUpdates2010

10. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis

Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis 19766640 2009 12 07 2009 12 24 2013 11 21 1528-0012 137 6 2009 Dec Gastroenterology Gastroenterology Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. 1934-43.e1-3 10.1053/j.gastro.2009.08.069 It is not clear what induction dose of mesalamine is optimal for treating patients with mildly (...) and moderately active ulcerative colitis (UC). This study was conducted to determine the efficacy and safety of mesalamine 4.8 g/day compared with 2.4 g/day for the treatment of moderately active UC. A multicenter, randomized, double-blind, 6-week, active-control study (ASCEND III) was conducted to assess the noninferiority of delayed-release mesalamine 4.8 g/day (Asacol HD, 800-mg tablet; Procter & Gamble, Pharmaceuticals, Inc, Mason, Ohio) with 2.4 g/day (Asacol, 400-mg tablet; Procter & Gamble

EvidenceUpdates2010

11. Erythrocyte-Mediated Delivery of Dexamethasone in Patients With Mild-to-Moderate Ulcerative Colitis, Refractory to Mesalamine: A Randomized, Controlled Study

Erythrocyte-Mediated Delivery of Dexamethasone in Patients With Mild-to-Moderate Ulcerative Colitis, Refractory to Mesalamine: A Randomized, Controlled Study 18721243 2008 10 15 2008 10 28 2013 11 21 1572-0241 103 10 2008 Oct The American journal of gastroenterology Am. J. Gastroenterol. Erythrocyte-mediated delivery of dexamethasone in patients with mild-to-moderate ulcerative colitis, refractory to mesalamine: a randomized, controlled study. 2509-16 10.1111/j.1572-0241.2008.02103.x Nearly 25 (...) % of patients with ulcerative colitis (UC) requiring steroids therapy become steroid-dependent after 1 yr, and virtually all develop steroid-related adverse events. We planned a controlled study to investigate the efficacy and safety of dexamethasone 21-P (Dex 21-P) encapsulated into erythrocytes (DEE). Forty patients with mild-to-moderate UC, refractory to mesalamine, were randomly assigned to one of the following three treatments: two DEE infusions 14 days apart (group A, N = 20), oral prednisolone (0.5

EvidenceUpdates2008

12. Mesalamine for induction of remission in patients with active mild to moderate ulcerative colitis

Mesalamine for induction of remission in patients with active mild to moderate ulcerative colitis Mesalamine for induction of remission in patients with active mild to moderate ulcerative colitis | Therapeutics Initiative Independent Healthcare Evidence > > Mesalamine for induction of remission in patients with active mild to moderate ulcerative colitis Belorussian translation (courtesy of Nadejda Dobkina): Background information of the condition: Ulcerative Colitis (UC) is the chronic (...) inflammation of colon and rectum. There is currently no known cure for ulcerative colitis, but it can be managed by medication. Based on four randomized controlled trials (RCTs) in 892 patients with UC, 5-ASA was found to be efficacious as compared to placebo in terms of induction of remission. Besides Mezavant®, there are 5 other mesalamine formulations available in Canada. In order to deliver mesalamine to the target site, oral tablets contain enteric coating, which allows mesalamine to be release above

Therapeutics Letter2008

13. A two-stage decision analysis to assess the cost of 5-aminosalicylic acid failure and the economics of balsalazide versus mesalamine in the treatment of ulcerative colitis

A two-stage decision analysis to assess the cost of 5-aminosalicylic acid failure and the economics of balsalazide versus mesalamine in the treatment of ulcerative colitis A two-stage decision analysis to assess the cost of 5-aminosalicylic acid failure and the economics of balsalazide versus mesalamine in the treatment of ulcerative colitis A two-stage decision analysis to assess the cost of 5-aminosalicylic acid failure and the economics of balsalazide versus mesalamine in the treatment (...) of ulcerative colitis Mackowiak J I Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of two oral 5-aminosalicylic acid (5-ASA) agents, balsalazide (6.75 g/day) and mesalamine (2.4 and 4.8 g/day), in the treatment of ulcerative

NHS Economic Evaluation Database.2006

14. Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis.

Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. 12878742 2003 07 24 2003 07 28 2013 11 21 1533-4406 349 4 2003 Jul 24 The New England journal of medicine N. Engl. J. Med. Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. 350-7 Epidermal growth factor (EGF) is a potent mitogenic peptide produced by salivary glands. We examined whether EGF enemas are an effective (...) treatment for active left-sided ulcerative colitis and ulceration limited to the rectum (proctitis). In a randomized, double-blind clinical trial conducted at Leicester Royal Infirmary, 12 patients with mild-to-moderate left-sided ulcerative colitis received daily enemas of 5 microg of EGF in 100 ml of an inert carrier and 12 received daily enemas with carrier alone for 14 days. All also began to receive 1.2 g of oral mesalamine per day or had their dose increased by 1.2 g per day. Patients were

NEJM2003

15. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.

A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. 9691103 1998 08 06 1998 08 06 2013 11 21 0028-4793 339 6 1998 Aug 06 The New England journal of medicine N. Engl. J. Med. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. 370-4 Crohn's disease is often treated with glucocorticoids or mesalamine. We compared the efficacy and safety of controlled-ileal-release (...) budesonide capsules and slow-release mesalamine tablets in patients with active Crohn's disease affecting the ileum, the ascending colon, or both. In a double-blind, multicenter trial, we enrolled 182 patients with scores of 200 to 400 on the Crohn's Disease Activity Index (with higher scores indicating greater disease activity) and randomly assigned 93 to receive 9 mg of budesonide once daily and 89 to receive 2 g of mesalamine twice daily for 16 weeks. The primary efficacy variable was clinical

NEJM1998

16. Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables

Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables Camma C, Giunta M, Rosselli M, Cottone M Authors' objectives To assess the effectiveness and tolerability of mesalamine in maintaining remission of quiescent Crohn's (...) disease, and to determine strategies for its optimal use. Searching MEDLINE was searched from 1986 to 1997 using the following MeSH terms: 'Crohn's disease', '5-aminosalicylic acid', 'mesalamine' or 'mesalazine'. Studies reported in any language were considered. THe reference lists of all available primary studies, review articles and congress abstracts were also checked. Study selection Study designs of evaluations included in the review Published randomised controlled trials (RCTs) comparing

DARE.1997